Ipamorelin is studied to better understand selective growth hormone receptor signaling, with particular interest in how it activates GH release without affecting other hormone pathways.

Ipamorelin belongs to the growth hormone-releasing peptide (GHRP) family but occupies a distinct position within it. Where earlier secretagogues like GHRP-6 and GHRP-2 produce measurable off-target hormonal responses — including cortisol and ACTH elevation — Ipamorelin’s functional activity is concentrated at the GHS-R1a receptor subtype responsible for somatotroph GH release, with negligible activity at receptor subtypes linked to adrenocortical and lactotroph signaling in preclinical assay systems.

This selectivity profile is its primary research value. It allows researchers to study GHS-R1a-mediated GH axis signaling in isolation — without the confounding hormonal background that less selective GHRPs introduce into assay systems. At the pituitary level, its GH-releasing potency reaches into the picomolar concentration range in preclinical models, making it an exceptionally potent and controllable tool compound for secretagogue receptor research.

Ipamorelin’s utility extends further when studied in combination with GHRH analogs. Co-administration with GHRHR agonists such as CJC-1295 (No DAC) or Sermorelin in preclinical preparations produces synergistic GH release responses — a well-characterized interaction that forms the scientific basis for dual-secretagogue combination research protocols.

• CAS Number: 170851-70-4
• Molecular Weight: 711.85 Da
• Purity: ≥99%
• Also Known As: NNC 26-0161, Ipamorelin acetate (salt form in some preparations)
• Chemical Formula: C₃₈H₄₉N₉O₅

In cell-based and preclinical models, Ipamorelin binds selectively to GHS-R1a — a Gq/11-coupled G protein-coupled receptor expressed on pituitary somatotroph cells — activating phospholipase C, IP3-mediated intracellular calcium release, and downstream PKC pathway stimulation. This calcium-dependent GH granule exocytosis mechanism is pharmacologically distinct from the cAMP/PKA pathway engaged by GHRHR agonists, which is central to the synergistic GH release observed when both receptor pathways are co-activated in somatotroph preparations.

In longer-duration preclinical models, Ipamorelin administration has been associated with increased GH pulse amplitude and elevated mean 24-hour GH concentrations without changes to pulse frequency — a pattern studied as a physiologically relevant GH secretion profile in GH-deficient rodent preparations. Downstream effects on bone mineral density markers in femoral and tibial preparations have been characterized by DEXA analysis in these models, and synergistic GH output has been confirmed when Ipamorelin is co-administered with GHRH analogs in combination secretagogue assay designs.

• GHS-R1a Selectivity and Receptor Binding Studies
• GH Secretion and Somatotroph Signaling Research
• Off-Target Hormonal Selectivity Profiling
• GH Pulse Amplitude and Pulsatility Modeling
• Dual-Secretagogue Combination Protocol Studies
• Bone Mineral Density Signaling in Preclinical Models
• GHRP Comparative Pharmacology and Potency Benchmarking